Studies have reported that treatment with BAY11-7082 could inhibit NLRP3 inflammasome activation, which indicated that BAY11-7082 was a potent inhibitor of the NLRP3 inflammasome independent of their inhibitory effect on the NF-κB pathway, and BAY11-7082 might represent an interesting approach for the management of psoriasis-like dermatitis depending on the dual inhibition of NF-κB and NLRP3 [59, 60]. This evidence concerns the gene NFKB1 and psoriasis.